AU2001276571A1 - Pharmaceutical combinations for treatment and prevention of diabetes mellitus - Google Patents
Pharmaceutical combinations for treatment and prevention of diabetes mellitusInfo
- Publication number
- AU2001276571A1 AU2001276571A1 AU2001276571A AU7657101A AU2001276571A1 AU 2001276571 A1 AU2001276571 A1 AU 2001276571A1 AU 2001276571 A AU2001276571 A AU 2001276571A AU 7657101 A AU7657101 A AU 7657101A AU 2001276571 A1 AU2001276571 A1 AU 2001276571A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- insulin
- usual
- optionally
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 abstract 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000006 Nitroglycerin Substances 0.000 abstract 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 abstract 1
- DLDKCSIJFIPYRK-UHFFFAOYSA-N Tenitramine Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O DLDKCSIJFIPYRK-UHFFFAOYSA-N 0.000 abstract 1
- BLJBDLGFKNXUCB-UHFFFAOYSA-N [2-methyl-2-(nitrooxymethyl)pentyl] nitrate Chemical compound [O-][N+](=O)OCC(C)(CCC)CO[N+]([O-])=O BLJBDLGFKNXUCB-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract 1
- 229960002479 isosorbide Drugs 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229940020630 methylpropylpropanediol dinitrate Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003402 propatylnitrate Drugs 0.000 abstract 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 229960004178 tenitramine Drugs 0.000 abstract 1
- 229960002485 trolnitrate Drugs 0.000 abstract 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP0002628 | 2000-07-14 | ||
| HU0002628A HUP0002628A2 (en) | 2000-07-14 | 2000-07-14 | Pharmaceutical combinations for treating diabetes |
| PCT/HU2001/000079 WO2002005795A2 (fr) | 2000-07-14 | 2001-07-13 | Combinaisons pharmaceutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001276571A1 true AU2001276571A1 (en) | 2002-01-30 |
Family
ID=89978472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001276571A Abandoned AU2001276571A1 (en) | 2000-07-14 | 2001-07-13 | Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040068005A1 (fr) |
| EP (1) | EP1303304B1 (fr) |
| JP (1) | JP2004503585A (fr) |
| AT (1) | ATE400298T1 (fr) |
| AU (1) | AU2001276571A1 (fr) |
| CA (1) | CA2415392A1 (fr) |
| DE (1) | DE60134747D1 (fr) |
| ES (1) | ES2311530T3 (fr) |
| HU (1) | HUP0002628A2 (fr) |
| WO (1) | WO2002005795A2 (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60331236D1 (de) * | 2003-07-24 | 2010-03-25 | Eswaran Krishnan Iyer | Orale zusammensetzungen zur behandlung von diabetes |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US8673964B2 (en) | 2004-05-20 | 2014-03-18 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| EP1700611A1 (fr) * | 2005-02-11 | 2006-09-13 | NOLabs AB | Dispositif de traitement de troubles dans la cavité buccale et son procédé de fabrication |
| WO2006084911A2 (fr) * | 2005-02-11 | 2006-08-17 | Nolabs Ab | Dispositif d'application de medicaments ameliore, procede de fabrication de celui-ci et procede de traitement |
| BRPI0606834A2 (pt) * | 2005-02-11 | 2009-07-21 | Nolabs Ab | usos de óxido nìtrico (no), dispositivo não implantável configurado, processo para fabricação de dispositivo configurado, uso de polìmero eluente de óxido nìtrico (no) e método de tratamento |
| DK1861130T3 (da) * | 2005-02-11 | 2009-01-26 | Nolabs Ab | Anordning og fremgangsmåde til behandling af dermatomycosis og navnlig onychomycosis |
| DE602006006432D1 (de) | 2005-03-24 | 2009-06-04 | Nolabs Ab | Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür |
| JP5246833B2 (ja) * | 2005-12-16 | 2013-07-24 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP5246834B2 (ja) * | 2005-12-27 | 2013-07-24 | 独立行政法人産業技術総合研究所 | アディポネクチン産生強化剤 |
| ITPI20060103A1 (it) * | 2006-08-07 | 2008-02-08 | Univ Pisa | Ibridi farmacodinamici con attivita' ipoglicemizzante e no-donor ottenuti dalla coniugazione di derivati idrossilati della glibenclamide con acidi carbossilici nitroossi-sostituiti. |
| US8822509B2 (en) | 2006-12-29 | 2014-09-02 | The University Of Queensland | Pain-relieving compositions and uses therefor |
| WO2008080194A1 (fr) * | 2006-12-29 | 2008-07-10 | The University Of Queensland | Compositions analgésiques et leurs utilisations |
| WO2010151240A1 (fr) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Composition topique contenant de l'ibuprofène |
| EP2445493A1 (fr) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Composition topique contenant du naproxène |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| CN103429247A (zh) | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
| WO2012092523A1 (fr) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systèmes et procédés de traitement d'allergies et autres indications |
| WO2013006608A1 (fr) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Compositions topiques |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| PL2854841T3 (pl) | 2012-06-04 | 2017-08-31 | Diamedica Inc. | Izoformy glikozylacji ludzkiej kalikreiny tkankowej 1 |
| US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| CN105979969B (zh) | 2013-08-08 | 2020-09-11 | 诺万公司 | 局部用组合物和使用所述组合物的方法 |
| US20150065423A1 (en) * | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
| CA2919733A1 (fr) | 2014-08-08 | 2016-02-08 | Novan, Inc. | Compositions topiques et methodes d'utilisation desdites compositions |
| US20180221385A1 (en) * | 2015-07-28 | 2018-08-09 | Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et | A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin |
| JP7090549B2 (ja) | 2016-03-02 | 2022-06-24 | ノヴァン，インコーポレイテッド | 炎症のための治療用組成物およびその治療方法 |
| CN109310630A (zh) | 2016-04-13 | 2019-02-05 | 诺万公司 | 用于治疗感染的组合物、系统、试剂盒和方法 |
| KR20190122706A (ko) | 2017-03-09 | 2019-10-30 | 다이어메디카 인코포레이티드 | 조직 칼리크레인 1의 투약 형태 |
| CN112920239B (zh) * | 2019-12-05 | 2023-03-28 | 天津医科大学 | α-葡萄糖苷酶诱导释放NO供体的制备及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3580384D1 (de) * | 1984-04-09 | 1990-12-13 | Toyo Boseki | Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle. |
| US5212154A (en) * | 1987-08-14 | 1993-05-18 | Akzo N.V. | Preparation for treating complications in diabetes |
| US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| ATE374607T1 (de) * | 1994-05-27 | 2007-10-15 | Strakan Int Ltd | Zusammensetzung enthaltend stickstoffoxid- donatoren und methode zur behandlung analer krankheiten |
| US6190704B1 (en) * | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
| JP4777489B2 (ja) * | 1997-03-31 | 2011-09-21 | ザ チルドレンズ メディカル センター コーポレーション | アポトーシス性酵素を不活性化するためのニトロシル化 |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
-
2000
- 2000-07-14 HU HU0002628A patent/HUP0002628A2/hu unknown
-
2001
- 2001-07-13 US US10/332,946 patent/US20040068005A1/en not_active Abandoned
- 2001-07-13 DE DE60134747T patent/DE60134747D1/de not_active Expired - Lifetime
- 2001-07-13 AT AT01954229T patent/ATE400298T1/de not_active IP Right Cessation
- 2001-07-13 AU AU2001276571A patent/AU2001276571A1/en not_active Abandoned
- 2001-07-13 JP JP2002511728A patent/JP2004503585A/ja not_active Withdrawn
- 2001-07-13 CA CA002415392A patent/CA2415392A1/fr not_active Abandoned
- 2001-07-13 EP EP01954229A patent/EP1303304B1/fr not_active Expired - Lifetime
- 2001-07-13 WO PCT/HU2001/000079 patent/WO2002005795A2/fr active IP Right Grant
- 2001-07-13 ES ES01954229T patent/ES2311530T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002005795A2 (fr) | 2002-01-24 |
| JP2004503585A (ja) | 2004-02-05 |
| EP1303304A2 (fr) | 2003-04-23 |
| HU0002628D0 (en) | 2000-09-28 |
| EP1303304B1 (fr) | 2008-07-09 |
| ATE400298T1 (de) | 2008-07-15 |
| WO2002005795B1 (fr) | 2003-01-30 |
| WO2002005795A3 (fr) | 2002-12-19 |
| HUP0002628A2 (en) | 2002-06-29 |
| DE60134747D1 (de) | 2008-08-21 |
| CA2415392A1 (fr) | 2002-01-24 |
| ES2311530T3 (es) | 2009-02-16 |
| US20040068005A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001276571A1 (en) | Pharmaceutical combinations for treatment and prevention of diabetes mellitus | |
| WO2005065069A3 (fr) | Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer | |
| RU2008142899A (ru) | Композиции далбаванцина для лечения бактериальных инфекций | |
| WO2011098539A1 (fr) | Traitement de la perte du sens du toucher avec des dérivés de saxitoxine | |
| RU2007133435A (ru) | Способ комбинированного лечения и применимые для этого сочетания лекарственных средств | |
| US3699229A (en) | 2-oxo-5-phenyl-4-oxazolidinone as an anti-depressant agent | |
| US20180140653A1 (en) | Compositions, kits and methods for treating type ii diabetes mellitus | |
| MXPA03003994A (es) | Composiciones de metformina de liberacion controlada. | |
| CA2435921A1 (fr) | Methode de therapie anticancereuse | |
| US6159986A (en) | Compounds and therapy for resisting memory loss in humans | |
| Schneider et al. | Dose-response relation of antianginal activity of isosorbide dinitrate | |
| TR200103144T2 (tr) | Yeni bileşikler | |
| CA2361081A1 (fr) | Traitement de la sclerose en plaques a la chaperonine 10 et au .beta.-interferon | |
| CA2283739A1 (fr) | Acide ascorbique agissant comme adjuvant dans le traitement de tumeurs malignes par chimiotherapie et radiotherapie | |
| DE4127469A1 (de) | Arzneimittel und ihre verwendung | |
| Calne | I‐Dopa in the treatment of parkinsonism | |
| WO2001093850B1 (fr) | Procede et compositions pour utiliser sulodexide dans le traitement de la nephropathie diabetique | |
| US3708593A (en) | Use of l-prolyl l-leucyl glycine amide as an anti-depressant | |
| WO2017126524A1 (fr) | Utilisation d'une association d'agents thérapeutiques anti-diabète | |
| CA2368352A1 (fr) | Procede de traitement de la neuro degenerescence | |
| AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica | |
| CA2409845A1 (fr) | Combinaison de substances comprenant un compose a effet opioide et un autre compose de la formule i | |
| DE2340515C3 (de) | Oral applizierbares Präparat für die Behandlung der Mykobakteriosen Lepra und Tuberkulose | |
| JP2001039998A (ja) | 癌進行抑制剤および抗癌剤 | |
| Simon et al. | Studies on the use of ethaverine in the treatment of angina pectoris |